IVPost
Harvard scientist gets American Heart Association award for identifying optimal treatments for cardiovascular disorders
- Details
- Written by AHA
- Category: Latest News
The American Heart Association presented its newest honor, the Joseph A. Vita Award, to Laura Mauri, M.D., of Harvard Medical School and Boston's Brigham & Women's Hospital, for her "leadership of transformative clinical investigations identifying and clarifying optimal treatment methodologies for a variety of cardiovascular disorders."
Quality of stent procedures consistently good across U.S. regardless of popular hospital ranking
- Details
- Written by American Heart Association
- Category: Medical News
Hospitals ranked among the best in cardiology and heart surgery by U.S. News and World Report appear no better at performing percutaneous coronary intervention (PCI), a potentially life-saving heart procedure, than unranked hospitals, according to preliminary research presented at the American Heart Association's Scientific Sessions 2017, a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians.
Practical approach to ensuring timely implementation of FDA’s menu labeling rule
- Details
- Written by FDA Commissioner Scott Gottlieb, M.D.
- Category: Latest News
As someone who enjoys eating out with my family and picking up the occasional take-out meal, I - like many Americans - want to know what's in the food I eat. As FDA Commissioner, I also know that more people are eating meals away from home, and our diets are increasingly comprised of foods we get from restaurants or take-out meals. FDA is committed to leveraging nutrition to enhance health and reduce disease, and the agency soon will be announcing a broader policy effort in this area. One important step is ensuring consumers have access to reliable and actionable information about the foods they eat so that they can make more informed choices about their diets and health for themselves and their families.
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer
- Details
- Written by Angela Stark
- Category: Medical News
The U.S. Food and Drug Administration expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
Implementation of FDA’s streamlined development and review pathway for consumer tests that evaluate genetic health risks
- Details
- Written by FDA Commissioner Scott Gottlieb, M.D.
- Category: Latest News
At a time when people are more aware of and engaged in their health care than ever before, genetic risk testing can provide helpful information about an individual's predisposition for certain diseases and conditions. These tests can prompt consumers to be more engaged in pursuing the benefits of healthy lifestyle choices and more aware of their health risks. Consumers are increasingly embracing genetic health risk (GHR) testing to better understand their individual risk for developing diseases. This engagement prompts some people to make more informed lifestyle choices.
Million Hearts® Recognizes the 2017 Hypertension Control Champions
- Details
- Written by IVP
- Category: Health News
The Centers for Disease Control and Prevention announced 24 winners of the 2017 Million Hearts Hypertension Control Challenge.
Page 41 of 50